FDA-approved
Hormones & metabolism
Tesamorelin
Evidence
FDA approved
Class
Growth hormone-releasing hormone analog
KEY TAKEAWAY
Tesamorelin is a growth hormone-releasing hormone analog approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.
Written by the Veylo editorial team · Updated
November 2026
What it is
A synthetic analog of growth hormone-releasing hormone
Approved for
Excess abdominal fat in HIV-associated lipodystrophy
Key fact
Reduced visceral abdominal fat in a randomized trial
Route
Daily injection
Evidence strength
FDA approved
Tesamorelin, sold as Egrifta, is a modified version of the 44-amino-acid hormone that triggers growth hormone release.
It stimulates the pituitary gland to release growth hormone, which raises IGF-1 and helps the body break down visceral fat.
The FDA approved tesamorelin in 2010 for reducing abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general weight loss.
Visceral fat reduction in adults with HIV on antiretroviral therapy. Other uses are investigational.
Joint pain, swelling, muscle aches and injection-site reactions occur. It can raise blood sugar and should not be used in active cancer.
Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359-2370.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.